BELLICUM PHARMACEUTICALS, INC 4
4 · BELLICUM PHARMACEUTICALS, INC · Filed Jul 6, 2017
Insider Transaction Report
Form 4
Spencer David M.
Chief Scientific Officer
Transactions
- Award
Stock Option (right to buy)
2017-07-03+26,250→ 26,250 totalExercise: $11.70Exp: 2027-07-02→ Common Stock (26,250 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the stock option vest and become exercisable on January 1, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.